Labiotech has curated a list of biotech movies that explore the intersection of science, technology, and humanity. From eugenics to genetic engineering, these films delve into the possibilities and consequences of emerging biotech trends. As the biotech industry continues to advance, these movies serve as a thought-provoking reflection on the potential implications of our actions….
Biotech on The Soothsayer / page 2
The biotech industry is expected to see significant advancements in 2025, with several companies working on innovative therapies for various diseases. Anavex Life Sciences, Candid Therapeutics, Enterprise Therapeutics, Jazz Pharmaceuticals, Life Biosciences, Ovid Therapeutics, Skye Bioscience, TG Therapeutics, Wave Life Sciences, and Quotient Therapeutics are among the companies to watch in 2025. These companies are…
A looming patent cliff threatens to disrupt the pharmaceutical industry, with over $200 billion in annual revenue at risk through 2030. However, this presents a significant opportunity for biosimilar developers to capitalize on the transition to more affordable treatments. Several companies, including Alvotech, Biocon Biologics, Celltrion, Formycon, and Samsung Bioepis, are already making strides in…
The holiday season is upon us, and with it comes the opportunity to gift our loved ones something unique and meaningful. Biotechnology-themed gifts are gaining popularity, and this article highlights some of the most interesting and innovative ideas. From glow-in-the-dark mushrooms to DIY biology kits, these gifts not only showcase the wonders of biotechnology but…
The article highlights six antisense oligonucleotide companies leading the way in this emerging field. These companies, including Ionis Pharmaceuticals, Isarna Therapeutics, Regulus Therapeutics, Sarepta Therapeutics, Secarna Pharmaceuticals, and Wave Life Sciences, are developing innovative treatments for various diseases. The global antisense oligonucleotides market is projected to grow significantly, driven by the ability of these treatments…
MicroRNAs (miRNAs) are small, non-coding RNA molecules that play a crucial role in regulating gene expression. Several companies are advancing candidates relying on miRNAs in 2024, with potential applications in disease diagnosis and treatment. Companies such as aceRNA Technologies, ARTHEx Biotech, and Transcode Therapeutics are developing innovative miRNA-based therapeutics for various diseases, including cancer, cardiovascular…
Gene therapy has emerged as a transformative approach in modern medicine, offering a potential cure for a wide array of genetic disorders. By introducing, modifying, or repairing genetic material within a patient’s cells, gene therapy aims to rectify underlying genetic defects, thereby treating or preventing disease. The field has witnessed significant milestones, with several gene…
The biotech industry is witnessing a surge in the development of bispecific antibodies, a type of targeted therapy that can deliver two-in-one treatments to patients with cancer and other diseases. Several companies, including Adaptin Bio, Akeso, AP Biosciences, Candid Therapeutics, Summit Therapeutics, and Zenas BioPharma, are working on various bispecific antibody candidates, some of which…
Eight biotech companies are making significant strides in breast cancer treatment, with innovative approaches and therapies showing promise in clinical trials. Arvinas, BioNTech, Carrick Therapeutics, Context Therapeutics, Hummingbird Bioscience, Oncolytics Biotech, Olema Pharmaceuticals, and Relay Therapeutics are among the companies pushing the boundaries of cancer treatment, offering new hope for patients and their families. In…
The biotech industry is witnessing a surge in the development of exosome therapy companies, which are harnessing the potential of these tiny vesicles to treat a range of diseases, including cancer, neurological disorders, and inflammatory diseases. With several companies advancing their candidates through clinical trials, the global exosome therapeutics market is expected to grow significantly…
